Amylyx reports Q3 2026 results with $768.1 million in cash and equivalents

what happened

According to TradingView, citing documents filed with the SEC, Amylyx recorded a third-quarter 2026 net loss of $45.5 million, or $0.38 per share. At September 30, the company held $768.1 million in cash, equivalents and marketable securities, of which about $544.6 million came from net proceeds of its August public offering.

Research and development spending rose to $28.4 million from $19.9 million a year earlier, while selling, general and administrative costs climbed to $21.3 million. The main quarterly milestone was the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, which met its primary endpoint with a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo, along with all secondary endpoints.

The drug was generally well tolerated during the double-blind period. Results will be presented as a late-breaking oral presentation on November 15 at ObesityWeek 2026. Amylyx plans to file the NDA by the end of 2026 and is preparing for a possible 2027 launch if approved. Enrollment in Cohort 3 of the AMX0114 ALS trial is complete, and Cohort 4 has started.

why it matters

Two points matter for the market: positive topline results from a key trial and a sizeable cash balance. Rising R&D and SG&A costs reflect preparation for filing and a possible launch, so quarterly losses may persist until commercialization. The shares will depend on the regulator's eventual decision.

market impact

Amylyx shares: the successful Phase 3 trial supports investor interest in the company.

• ▲Amylyx shares pressure up — positive Phase 3 data reduces uncertainty around the drug's regulatory path

tags

instruments